Pratteln, Switzerland, June 23, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces positive topline results from itslong-term Phase 4 LEROS study with Raxone® (idebenone) in the treatment of ...
Pratteln, Switzerland, February 8, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that it has secured a final reimbursement agreement with the French authorities related to Raxone® (idebenone) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results